Shree Ganesh Biotech Q2 Results: Net Loss of Rs 0.08 Crore

Revenue for the quarter fell to Rs 0.16 crore from Rs 0.77 crore in the same period last year.

Reader Takeaway: Revenue contraction and newly acquired debt pressure the company as it shifts from profitability to losses.

What just happened

Shree Ganesh Biotech (India) Ltd reported financial results for the quarter ended September 30, 2026, showing a transition from a profit-making entity to a loss-making one. The company posted a net loss after tax of Rs 0.08 crore for the quarter, compared to a profit of Rs 0.01 crore in the corresponding quarter of the previous fiscal year. For the half-year period, the loss stands at Rs 0.65 crore, a stark reversal from the Rs 0.34 crore profit recorded in the first half of the previous year.

Why this matters

The sharp decline in revenue and the emergence of operational losses reflect significant headwinds. The company’s revenue from operations saw a sharp year-on-year drop and a sequential decline compared to the Rs 1.43 crore reported in the previous quarter ending June 30, 2026.

Balance Sheet and Debt

A significant shift in the company’s capital structure is the introduction of Rs 11.00 crore in current borrowings, which were not present as of March 31, 2026. Simultaneously, inventory levels have ballooned to Rs 22.82 crore from Rs 11.73 crore at the end of the previous fiscal year, suggesting a potential buildup in stock alongside increased debt obligations.

What to track next

Investors should monitor the company’s cash flow management and its ability to clear the newly reported short-term debt. Given the decline in top-line growth, market observers will be watching for management's strategy to improve operational efficiency and return to a profitable state in coming quarters.